GET taps into indigenous human capital, focuses on distinct service and research areas of emerging pathogens and collaborates with governments to cascade our programs. We work with the best and most effective partners and will strive constantly to provide high quality and impact focused results to Africa and funders alike.


Site visit to Military Hospital in Sierra Leon February 2015.


  • The GET is a Action can only be taken within and according to the Terms of Reference. The GET is a legal non-profit entity, registered in Ghana, Nigeria and the United States of America.
  • The GET is currently in the process of registration as a Non- Governmental Organization in Nigeria, West Africa.
  • The GET is administered by the Executive Steering Committee with oversight from the Board of Members of the consortium are functional in structured Working Groups which provide the participants the opportunity to discuss matters and implement strategic plans which fall within the Terms of Reference of the respective working groups. The Chair of the Executive Steering Committee is the Principal Investigator (PI) of GET, supported by 5 Regional Chairs and major funding partners.The PI will be in regular contact with the Chair of the Board of the Advisors receiving guidance for major operational advise. The Executive Steering defines the executive direction of the Consortium through the Steering Committee which is comprised of additional members drawn from the major international partners and the chairs of the working groups.
  • The products of the working groups will be presented to the Steering Committee and the Consortium at large.
  • Initiative recommendations will be made by consensus and will only be addressed to the initiative participants.

GET operational team hosts of the Freetown Survivors conference Feb 2015;

Left to Right: Nelson Makamo, Freda Suglo, Dr. Brian Conton, Lungi Morrison, Prof. Akin Abayomi, Prof Sahr Gevao.


  • To anticipate in advance through surveillance and data gathering the possibility of the emergence of dangerous pathogens on the continent of Africa.
  • To anticipate the entry of emerging pathogens into the continent and make appropriate recommendation to minimize risk.
  • To identify conditions that lead to the emergence of dangerous pathogens such as conflict and environmental perturbations and make necessary recommendations to mitigate such risk.
  • To assess the capacity both in terms of infrastructure and human capital that is necessary to respond with speed to early warning signs suggestive of the emergence of a dangerous pathogen outbreak.
  • To conduct research into preceding and current outbreaks in a harmonized fashion across the
  • To develop the framework for ethical and community acceptable research and medical interventions that is cognizant of the culture and belief systems of the indigenous people of the continent and which engenders trust.
  • To disseminate in a timely fashion the findings of research conducted.
  • To act as a conduit for access to expertise by international responders in scenarios where outbreaks create state of emergencies and to facilitate collaborative relationships in fashion that does not impose a threat to sovereignty and dignity of the continent.
  • To promote high level advocacy necessary for ensuring political will is focused on appropriate spending on research and development necessary to fast track all of the above.
  • To develop capacity building for the effective development of blood plasma products on the continent of Africa.
  • To develop the technology platforms for the monitoring and safety of patient data and biodata.
  • To facilitate global support for targeted vulnerable populations.
  • To facilitate regulatory frameworks and guidelines for informing research into emerging pathogens on the continent.